PSTI – An Under the Radar Small Cap Biotech Company

Pluristem Therapeutics Inc. (PSTI) Nasdaq   PLURISTEM (PSTI) a cell therapy company, developer of placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory and hematologic conditions, company I’m.

A Quick Technical Look At SRPT Full Year Chart

Sarepta Therapeutics, Inc. (SRPT) Nasdaq   A quick look at Sarepta’s yearly chart, from the spike to $63.73 after Exondys-51 FDA approval and the drop to $26.66 lowest point by Dec.

SRPT – Preparing For Blast Of Catalysts

Already a year has passed since Sarepta’s first drug Exondys51 was granted FDA approval on 09/19/2016. The landmark decision by Janet Woodcock, despite the review team’s opposition, gave hope to.

A Deep Dive in SRPT Chart!

Sarepta Therapeutics, Inc. (SRPT) -Nasdaq During the past six weeks we had so many stories, with or against SRPT approval, where a 10-million shares short sellers are still traped in.

TRIL – A quick update from BloomBurton 2016 conference

  Trillium Therapeutics Inc. (TRIL) – Nasdaq   Trillium Therapeutics (TRIL) presented at BloomBurton-2016 Healthcare Investor Conference in Toronto on May 3rd, the same as last year the speaker was TRIL’s Chief.

SRPT – Final thoughts ahead of the AdCom

  Reaching the decision point… Today is the day we have to make decisions in SRPT position. As has been explained several times in the forum and CRG twitter private.

SRPT – YEAR 4 DATA ANALYSIS

  YEAR 4 DATA ANALYSIS Review of Eteplirsen to treat DMD By: @boscaptn, et al.   Compiled From SAREPTA Public Data For Week 216 (Year 4) of Study 201/202 for.

Biotech Inflection Point – Watch List-2

  Following my last technical analysis “Biotech Inflection Point – Watch List-1” I will keep adding names to our watch list with some beaten down tickers, we can find many.

Biotech Inflection Point – Watch List-1

  Following my last technical analysis “XBI – A Look At The Near and Long Term In The Biotech Sector” I will start adding names to our watch list with.

XBI – A Look At The Near and Long Term In The Biotech Sector

  SPDR S&P Biotech ETF (XBI)–NYSE   We will maintain our focus on the XBI as the biotech barometer, many are waiting for the XBI to outperform the IBB again.

The XBI In The Take Or Break Zone!

  SPDR S&P Biotech ETF (XBI)–NYSE   We will maintain our focus on the XBI as the biotech barometer. After the double bottom around 59 points a month ago, the.

Sarepta Patent Issue – Ask The USPTO Reg Attorney

  This week BioMarin (BMRN) announced it won the first  DMD patent battle against Sarepta (SRPT) in a press release stating, “BioMarin Receives Favorable Ruling in the Use of Exon.

2 Biotech Stocks In The Breakout Territory

  Biotech traders have to adapt to any changes in the stock market, trying to adjust their trades and the game plan along with the markets condition. It is easier.

SRPT Breakout- A Quick Look At The Chart

  Sarepta Therapeutics, Inc. (SRPT) – Nasdaq   After three years of a roller coaster, Sarepta getting closer to the the real deal, started with the NDA acceptance by the FDA on.

A Quick look – XBI In The Decision Zone

SPDR S&P Biotech ETF (XBI) We will maintain our focus on the XBI as the biotech barometer. Noticing lately the fact XBI is outperforming the IBB & the broader market.

BioBlast Pharma: an under the radar ultra-rare disease company

  Bio Blast Pharma Ltd. (ORPN) – Nasdaq BioBlast Pharma (ORPN) is a clinical-stage biotech company, focused on treatments for rare and ultra-rare diseases, especially genetic and metabolic diseases. The company has three.

TRIL – Preparing For The Next Move Upward

  Trillium Therapeutics Inc. (TRIL) – Nasdaq Trillium (TRIL) is developing the next-generation of cancer immunotherapies. TRIL’s lead program, SIRPαFc, targets CD47 to prevent cancer cells from delivering a “do not eat”.

Quick update from TRIL Presentation in Toronto

  Trillium Therapeutics Inc. (TRIL) – Nasdaq   Trillium Therapeutics presented at Bloomburton-2015 Healthcare Investor Conference in Toronto on May 5th, the speaker Dr. Rob Uger, TRIL’s Chief Scientific Officer (CSO) was.

BMY – Is the Technical Correction Done ?

  Bristol-Myers Squibb Company (BMY) –NYSE   Bristol-Myers Squibb Co. (BMY) had a wild year, up from the lows of $47.54 in mid October 2014 to reach a new 12 years high.

Adamas Pharmaceuticals – Volatility Squeeze Action

  Adamas Pharmaceuticals, Inc. (ADMS) –Nasdaq   Adamas pharmaceutical had its initial public offering last year April 10th, the closing of its IPO of 3 million shares at a public offering.

Quick update: The IBB – Negative Divergence

iShares Nasdaq Biotechnology (IBB) – Nasdaq As tweeted several time last and early this week, signs of weakness in the IBB Signs of weakness in the $IBB ..Start forming a Bearish.

IBB – XLV Biotech Sector Post JP-Morgan Conference

  iShares Nasdaq Biotechnology (IBB) – Nasdaq Health Care Select Sector SPDR ETF (XLV)–NYSE   The best indicators for our biotech portfolios are the biotechnology indices IBB, NBI, XBI or XLV..

BMY – A Bull Flag Breakout or A Head Fake

  Bristol-Myers Squibb Company (BMY)  -NYSE Interesting price action since October 15th, after touching the support line $47.52 and bouncing back to start a new uptrend, we were looking to reach.

Caution, SPY – Forming A Rare Tri-Star Pattern

  SPDR S&P 500 ETF (SPY) –NYSE The SPY had an extreme price action during the last two months after reaching the All-Time-High 201.90 points on September 19th, followed by a.

MRK – A Falling Knife Or a Golden Opportunity

  Merck & Co. Inc. (MRK) -NYSE Many speculation going around the huge drop in MRK’s share price in just one week, dropping from the $60.18 (closing on 10/08) to reach.

CNAT – A Quick Chart Update

  Conatus Pharmaceuticals Inc. (CNAT) –Nasdaq CNAT was trading within a downtrend channel since June 16th after reaching the high of $9.90, finding a base around the $6.00 weekly support line.

SRPT- A Squeeze In The Making

  Sarepta Therapeutics, Inc. (SRPT)-Nasdaq   Sarepta is preparing for a busy 4th quarter ahead of the NDA submission as confirmed again by the company’s CEO Chris Garabedian during the Morgan.

Merck – Preparing For The Next Move

  Merck & Co. Inc. (MRK) -NYSE   Lately, Merck was under the spot light after Idenix Pharmaceuticals deal, paying $3.85 Billion more than triple Idenix’s market capitalization before the deal.

SPY – A Quick Look at The Broader Market

SPDR S&P 500 (SPY) –NYSE   Yesterday we got a sharp turn in the SP-500 as the daily chart of the SPY (S&P 500 ETF) drops sharply and breaks down the.

Tekmira – Is It The Bottom Yet

  Tekmira Pharmaceuticals Corp (TKMR) –Nasdaq   Tekmira is the new “fallen star” after the wild run started Jan 07th, 2014 from $7.66, and reaching the all time high $31.48 mid.

BMY – In The Inflection Point

  Bristol-Myers Squibb Company (BMY) –NYSE   Bristol-Myers Squibb Co. (BMY) had a wild year, up from the lows of $41.11 in late August 2013 to reach a new 12 years.

Browsing 31 / articles